Viatris Inc. VTRS
19.88 USD -0.40 (-1.97%)
Regular-session close
19.88 0.00 0.00%
Pre-market · Nov 20, 4:35 AM ET
19.69 Day range 20.34
10.15 52-week range 21.20
- YTD
- +59.68%
- 1 year
- +95.09%
Benzinga news
benzinga.com Oppenheimer Maintains Outperform on Viatris, Raises Price Target to $26 Oppenheimer analyst Les Sulewski maintains Viatris (NASDAQ:VTRS) with a Outperform and raises the price target from $25 to $26.
benzinga.com David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes DME Capital Management reveals its new third-quarter stock picks. Here's what David Einhorn has been buying.
benzinga.com United Natural Foods To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts raised price targets for CG Oncology, Viatris, Rubrik, Allarity, IDACORP, Tyson Foods and Range Resources.benzinga.com Leerink Partners Maintains Outperform on Viatris, Raises Price Target to $24 Leerink Partners analyst Daniel Clark maintains Viatris (NASDAQ:VTRS) with a Outperform and raises the price target from $22 to $24.
benzinga.com Barclays Maintains Overweight on Viatris, Raises Price Target to $25 Barclays analyst Glen Santangelo maintains Viatris (NASDAQ:VTRS) with a Overweight and raises the price target from $22 to $25.
benzinga.com Viatris Q3 2026 Earnings Call Transcript Viatris (NASDAQ:VTRS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Viatris Raises FY2026 Adj EPS Guidance from $2.45-$2.49 to $2.56-$2.63 vs $2.51 Est; Narrows FY2026 Sales Guidance from $14.550B-$14.950B to $14.700B-$14.900B vs $14.788B Est Viatris (NASDAQ:VTRS) raises FY2026 Adj EPS guidance from $2.45-$2.49 to $2.56-$2.63 vs $2.51 analyst estimate. Narrows FY2026 sales outlook from $14.550 billion-$14.950 billion to $14.700…
benzinga.com Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr Viatris Inc. ("Viatris") (NASDAQ:VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to
benzinga.com Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $14 Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $13 to $14.
benzinga.com JP Morgan Maintains Neutral on Viatris, Raises Price Target to $20 JP Morgan analyst Chris Schott maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $18 to $20.
